We perform cytogenetic and FISH analysis for our inpatient population, community-based physicians and independently run pathology laboratories. Our goal is to provide the community with exceptional care and quality service.
Under the leadership of Joyce Murata-Collins, Ph.D. (ABMGG board-certified clinical cytogeneticist, director), and Jia-Chi (Jack) Wang, Ph.D., the Cytogenetics Service performs over 8,000 diagnostic cancer cytogenetic and fluorescence in situ hybridization (FISH) procedures annually with an overall abnormality rate of approximately 32.2 percent. Testing to detect and characterize leukemias, lymphomas and solid tumors is performed on fresh and archival FPE (formalin-fixed, paraffin-embedded) tissues.
A Premier Diagnostic Facility
Advanced testing methodologies are utilized for:
G-banded Chromosome Analysis
FISH Oncology Detection Assays:
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma Targeted Plasma Cell
Neuroblastoma — MYCN/CEP2
Ewing Sarcoma — EWSR1
Synovial Sarcoma — SS18
Alveolar Rhabdomyosarcoma — FOX01A
Principal Investigator: Joyce Murata-Collins, Ph.D.
The director in Cancer Cytogenetics, Joyce Murrata-Collins' research focuses on leukemia, lymphoma and multiple myeloma.